BOSTON SCIENTIFIC CORP BSX
NYSE · XNYS · stock · Surgical & Medical Instruments & Apparatus
Chart by TradingView
5/9
Piotroski F — financial health
2.78
Altman Z″ — distress risk · safe
—
Dividend payout · no dividend
Financials (annual, from 10-K)
| FY | Revenue | Net income | Gross profit | Free cash flow | Equity |
|---|---|---|---|---|---|
| 2025 | $20.1B | — | $13.9B | $3.7B | $24.2B |
| 2024 | $16.7B | — | $11.5B | $2.6B | $21.8B |
| 2023 | $14.2B | — | $9.9B | $1.8B | $19.5B |
| 2022 | $12.7B | — | $8.7B | $938.0M | $17.6B |
| 2021 | $11.9B | — | $8.2B | $1.3B | $16.6B |
| 2020 | $9.9B | — | $6.4B | $1.1B | $15.3B |
Why these scores methodology →
Piotroski F-score: 5/9
- Positive return on assets
- Positive operating cash flow
- Rising ROA
- Cash flow exceeds net income
- Lower long-term debt
- Rising current ratio
- No share dilution
- Rising gross margin
- Rising asset turnover
Altman Z″: 2.78 (safe)
- Working capital / assets 0.077
- Retained earnings / assets 0.128
- EBIT / assets 0.083
- Equity / liabilities 1.247
Source: SEC EDGAR filings · CIK 0000885725 · as of 2025-12-31. Figures are facts from filings plus Stocktoria's own computed scores — not investment advice.